Peptide News Digest

#Melanotan-Ii

3 stories

Industry · View digest

LEO Pharma Announced Tuesday August 18, 2026 an Agreement to Acquire Worldwide Rights to Dersimelagon (Formerly MT-7117), a Selective Melanocortin-1 Receptor (MC1R) Agonist Small-Molecule Compound Being Developed for Erythropoietic Protoporphyria (EPP) and X-Linked Erythropoietic Protoporphyria (XLEPP), From Japanese Drugmaker Mitsubishi Tanabe Pharma; Dersimelagon Is Currently in Phase 3 Trials Across Multiple Rare Photodermatoses Indications and Represents an Oral Alternative to the Currently-Approved Injectable Melanocortin-Axis Therapies Including Clinuvel's Scenesse (Afamelanotide, an Alpha-MSH Analog Peptide for EPP) and Rhythm Pharmaceuticals' IMCIVREE (Setmelanotide, an MC4R Agonist Peptide for Rare Genetic Obesity Syndromes and Acquired Hypothalamic Obesity)

LEO Pharma announced Tuesday August 18, 2026 an agreement to acquire worldwide rights to dersimelagon (formerly MT-7117) from Japanese drugmaker Mitsubishi Tanabe Pharma. Dersimelagon is a selective melanocortin-1 receptor (MC1R) agonist small-molecule compound being developed for erythropoietic protoporphyria (EPP) and X-linked erythropoietic protoporphyria (XLEPP), rare inherited photodermatoses in which patients develop severe skin pain and burning after light exposure. Dersimelagon is currently in Phase 3 trials across multiple rare photodermatoses indications. The mechanism: MC1R agonism stimulates skin cells (melanocytes) to produce more melanin, which absorbs light and reduces the pain-generating reaction to sun exposure that characterizes EPP. Dersimelagon represents an oral small-molecule alternative to the currently-approved injectable melanocortin-axis therapies including Clinuvel's Scenesse (afamelanotide, an alpha-MSH analog peptide administered as a subcutaneous implant for EPP, approved US 2019) and adjacent to Rhythm Pharmaceuticals' IMCIVREE (setmelanotide, an MC4R agonist peptide for rare genetic obesity syndromes and acquired hypothalamic obesity, approved US 2020 with the acquired hypothalamic obesity extension approved June 2026). The LEO Pharma acquisition extends the melanocortin therapeutic franchise landscape and positions LEO for a broader dermatology and rare-disease portfolio alongside its existing psoriasis and atopic dermatitis commercial franchises. Financial terms were not fully disclosed. The transaction adds to the growing melanocortin-axis drug development activity across peptide (afamelanotide, setmelanotide, melanotan II) and small-molecule (dersimelagon) modalities.

Regulatory · View digest

FDA Pharmacy Compounding Advisory Committee (PCAC) Has Scheduled a Second Peptide Meeting Before the End of February 2027 to Review Five Additional Peptides for Section 503A Bulks List Inclusion Following the July 23-24, 2026 Session That Recommended 6 of 7 Peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP Rejected); The February 2027 Docket Covers Cathelicidin (LL-37, Antimicrobial Peptide With Broad Anti-Infective and Immune-Modulatory Activity), GHK-Cu (Copper Tripeptide Widely Marketed in Cosmetic and Wound-Healing Formulations), Dihexa Acetate (Angiotensin-Derived Nootropic), Melanotan II (α-MSH Analog for Skin Pigmentation and Appetite Suppression), and Pegylated Mechano Growth Factor (PEG-MGF, Muscle Repair Peptide)

The FDA Pharmacy Compounding Advisory Committee (PCAC) has scheduled a second peptide meeting before the end of February 2027 to review five additional peptides for Section 503A Bulks List inclusion. The February 2027 docket covers: cathelicidin (LL-37), a broad-spectrum antimicrobial peptide with anti-infective and immune-modulatory activity; GHK-Cu (glycyl-histidyl-lysine copper tripeptide), a widely-marketed cosmetic and wound-healing peptide previously in FDA Category 2; dihexa acetate, an angiotensin IV-derived nootropic that has been marketed for cognitive enhancement; melanotan II, an alpha-melanocyte-stimulating hormone analog marketed for skin pigmentation (self-tanning) and appetite suppression; and pegylated mechano growth factor (PEG-MGF), a muscle-repair peptide derived from insulin-like growth factor 1 splice variants. The February 2027 review continues the July 23-24, 2026 PCAC session that recommended 6 of 7 peptides for Section 503A Bulks List inclusion (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon approved; Emideltide/DSIP rejected). FDA has not yet posted the final date and public-comment docket details for the February 2027 meeting. Under standard rulemaking timelines, the FDA's process of Notice of Proposed Rulemaking, public comment period, and final rule after any positive PCAC recommendation takes 12-24 months.

Regulatory · View digest

FDA Confirms Second PCAC Meeting Before End of February 2027 — GHK-Cu (Injectable), Melanotan II, Cathelicidin LL-37, Dihexa Acetate, PEG-MGF for 503A Bulks-List Review

The FDA confirmed the Pharmacy Compounding Advisory Committee will convene a second meeting before the end of February 2027 to review five additional peptides for potential 503A Bulk Drug Substances List inclusion: GHK-Cu (injectable formulation specifically — topical/cosmetic remains separate), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, and Mechano Growth Factor Pegylated (PEG-MGF). The February 2027 meeting follows the July 23-24, 2026 PCAC that will review seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2). Compounding pharmacies cannot legally compound these five peptides until the PCAC review concludes and the FDA issues a final determination — a 6-12 month timeline post-meeting. The peptide-specific indications under review span aesthetic dermatology (GHK-Cu, Melanotan II), antimicrobial activity (LL-37), neuroprotection (Dihexa), and growth-factor-mediated tissue regeneration (PEG-MGF).